HOME >> MEDICINE >> NEWS
Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions

SAN DIEGO - The results of a Phase I/II study of NUVANCE™ (IL-4 receptor) in adult patients with moderate asthma will be featured at the Late-Breaker Abstract Session at the American Academy of Allergy, Asthma and Immunology's (AAAAI) 56th Annual Meeting (March 3-8 in San Diego, California).

WHEN: Saturday, March 4, 2000, 3:00 pm

WHERE: Late Breaker: New Therapies Mini-symposium, Room 8, Upper Level of the San Diego Convention Center.

WHO: Dr. Jonathan Corren, MD, Medical Director, Allergy Research Foundation, and lead investigator will present the results of Phase I/II study of NUVANCE™ in adult patients with moderate asthma. Dr. Corren is affiliated with the University of California, Los Angeles.

A presentation entitled, "Cytokines and Cytokine Therapy for Allergic Diseases: Which One is the Most Critical? Il-4 and IL-4 Receptor Antagonists in Allergic Disease," will also be featured at the AAAAI Annual Meeting.

WHEN: Monday, March 6, 2000, 8:45 am - 10:45 am

WHERE: Asthma Therapy Symposium, Marina Ballroom G, Level 3, South Tower, Marriott.

WHO: Dr. Jan Agosti, Medical Director, Immunex Corp., will present scientific evidence and clinical data demonstrating the potential of IL-4 inhibition to improve lung function and control the symptoms of people with asthma.

Interleukin-4 (IL-4) is a naturally occurring cytokine, or immune system protein, that has been commonly associated with the development of asthma and allergies. It binds to specific IL-4 receptors (IL-4R) on the surface of cells in the body or to naturally occurring soluble receptors that circulate throughout the body. Increased levels of IL-4 appear to be related to increased severity of asthma that results in difficulty in breathing. Immunex scientists used recombinant DNA technology to produce a soluble IL-4 receptor, a molecule the company names NUVANCE. When IL-4 binds with NUVANCE instead of cell-surface IL-4R, the effects of IL-4 may be block
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
1-Mar-2000


Page: 1 2

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
8. Results of NUVANCE phase I/II asthma trial presented
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. UI Study Yields Encouraging Results For New Breast Cancer Treatment
11. Ph.D. Degree Research Results In Patent For Low-Cost Pharmaceutical Filters Made From Seafood Waste

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... ... 19, 2019 , ... Marking a key milestone in the ... on Wednesday will lift into place the final steel beam at AHN ... year. , The nearly 79,000-square-foot facility – located at 6321 Route 30, Greensburg, ...
(Date:2/19/2019)... HILLS, Calif. (PRWEB) , ... February 19, 2019 ... ... Wachler Vision Institute, Brian Boxer Wachler, MD, has launched the first ever supplement ... that can lead to severe to severe vision loss. The supplement, KC Defense, ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... with town halls across the country , A partnership between Liberty University and ... crisis, continues with its next town hall event on Tuesday, February 19, at ...
(Date:2/19/2019)... JACKSONVILLE, Fla. (PRWEB) , ... February 19, 2019 ... ... professors say yes! , “Nova Filtration is based in The Villages FL proudly ... success in our new franchised Territory in the greater Jacksonville area selling and ...
(Date:2/19/2019)... ... February 19, 2019 , ... Dr. Lombardi is ... Oncology Institute of Hope and Innovation. , Dr. Lombardi completed his undergraduate in ... received his medical degree from the University of Rochester School of Medicine. He ...
Breaking Medicine News(10 mins):
(Date:2/16/2019)... ... February 15, 2019 , ... ... Allison Marlow of Perio-Implant Care are urging patients to take their oral health ... cancers, diabetes, Alzheimer's and dementia, and risk of pre-term birth, there is plenty ...
(Date:2/16/2019)... ... 15, 2019 , ... Dr. Lucas Bryant, board-certified Face expert ... Haute Beauty Network, well known for their exclusivity, and luxurious lifestyle, is privileged ... newest addition to the Haute Living partnership. , Haute Beauty offers a prominent ...
(Date:2/14/2019)... Colo. (PRWEB) , ... February 14, 2019 , ... ... Month , Lewis and Clark College Emeritus Professor of Education Gregory A. Smith ... They discuss the emergence of Brand Ambassador programs, a new phenomenon in the ...
Breaking Medicine Technology:
Cached News: